Chun Loo Gan - Concepedia

Author

Chun Loo Gan

Harvard University ORCID

Also Known As

C. Gan, C.L. Gan, Chun Gan, Chun L. Gan, Chun Loo Gan, Chun Loo Gan, Gan, Chun, J. Deane

Publications

941

Citations

H-Index

Concepts

All Affiliations

Harvard University University of Calgary Dana-Farber Cancer Institute Aarhus University Hospital City of Hope

About

Chun Loo Gan is an author at Harvard University specializing in medicine, urology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	322
2	Health Sciences	2	2	31
3	Public Health	1	1	11
4	Allergy	1	1	13
5	Emergency Medicine	1	1	20

Chun Loo Gan

Publications

720

Citations

H-Index

Page 1

	Year	Citations
Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival Shaan Dudani, Guillermo de Velasco, J. Connor Wells, JAMA Network Open	2021	273
Upfront Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors or Targeted Therapy: An Observational Study from the International Metastatic Renal Cell Carcinoma Database Consortium Ziad Bakouny, Talal El Zarif, Shaan Dudani, European Urology Surgical OncologyUpfront Cytoreductive NephrectomyUrologyGenitourinary CancerMedicine	2022	103
Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial Edmond M. Kwan, Lavinia Spain, A. Antón, European Urology Ice-pac Clinical TrialSurgical OncologyUrologyRadiation TherapyMedicine	2021	65
Outcomes of patients with solid tumour malignancies treated with first-line immuno-oncology agents who do not meet eligibility criteria for clinical trials Chun Loo Gan, Igor Stukalin, Daniel E. Meyers, European Journal of Cancer	2021	46
Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium Chun Loo Gan, Shaan Dudani, J. Connor Wells, Cancer Medicine	2021	38
Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy Jeffrey Graham, J. Connor Wells, Shaan Dudani, European Journal of Cancer UrologyCancer ImmunosurveillanceGenitourinary CancerMedicineImmunology	2022	34
Klotho inhibits renal ox-LDL deposition via IGF-1R/RAC1/OLR1 signaling to ameliorate podocyte injury in diabetic kidney disease Wei Jiang, Chun Loo Gan, Xindi Zhou, Cardiovascular Diabetology	2023	29
Sites of metastasis and survival in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC). Shaan Dudani, Guillermo de Velasco, Connor Wells, Journal of Clinical Oncology Surgical OncologyCancer ManagementPrognosisPathologyMultimodality	2020	28
Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) – an International mRCC Database Consortium (IMDC) analysis Daniel Vilarim Araújo, J. Connor Wells, Aaron R. Hansen, Journal of Geriatric Oncology UrologyGenitourinary CancerImmune-checkpoint InhibitorsMedicineImmunology	2021	24
Cytoreductive nephrectomy (CN) for metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or targeted therapy (TT): A propensity score-based analysis. Ziad Bakouny, Wanling Xie, Shaan Dudani, Journal of Clinical Oncology Propensity Score-based AnalysisSurgical OncologyPrognosisClinical SpecialtiesLogistic Analysis	2020	20

Page 1